At a glance
A GnRH analogue whose effects depend strongly on delivery pattern.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The cited context includes reproductive hormones and fertility-related outcomes. Diagnostic use, pulsatile therapy and informal dosing schedules should not be treated as equivalent.[1][5][7]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Gonadorelin.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 2 mg · 2 source tables
Standard / Maintenance Approach (2 mL = 1 mg/mL)
| Week/Phase | Dose per Injection (mcg) | Units (mL) |
|---|---|---|
| Weeks 1–2 (Initiation) | 50 mcg | 5 units (0.05 mL) |
| Weeks 3–4 (Titration) | 100 mcg | 10 units (0.10 mL) |
| Weeks 5–8 (Maintenance) | 100–150 mcg | 10–15 units (0.10–0.15 mL) |
Route: Subcutaneous injection. Frequency: 2–3 times per week on non‑consecutive days (e.g., Mon/Wed/Fri or Tue/Thu/Sat). For ≤10‑unit (≤0.10 mL) administrations, consider 30‑ or 50‑unit insulin syringes for improved readability.
Advanced / Post‑Cycle Support Approach
| Week/Phase | Dose per Injection (mcg) | Units (mL) |
|---|---|---|
| Days 1–7 (Burst) | 200 mcg | 20 units (0.20 mL) |
| Days 8–14 (Taper) | 100 mcg | 10 units (0.10 mL) |
| Week 3+ (Optional Maintenance) | 100 mcg 2–3×/wk | 10 units (0.10 mL) |
Route: Subcutaneous injection. Frequency: Daily or every other day for short cycles (limit to ≤14 consecutive days to avoid pituitary desensitization). Important: Limit consecutive daily dosing to ≤14 days. Extended continuous administration may lead to GnRH receptor desensitization and reduced LH/FSH response[4]. Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Additional schedule context & duration
Concise summary of the periodic micro‑dosing regimen.
- Goal: Stimulate endogenous LH and FSH release to support testosterone production and testicular function[1][5].
- Schedule: Subcutaneous injections 2–3 times weekly for 4–8 weeks; limit daily dosing to ≤14 consecutive days.
- Dose Range: 50–200 mcg per injection based on goals and response.
- Reconstitution: 2.0 mL per 2 mg vial (1 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested periodic titration approach.
- Start: 50–100 mcg per injection; assess tolerance before increasing.
- Target: 100–150 mcg per injection, 2–3 times weekly.
- Frequency: Non‑consecutive days (e.g., Mon/Wed/Fri) to mimic pulsatile GnRH release.
- Cycle Length: 4–8 weeks; include off‑periods to maintain pituitary sensitivity.
- Timing: Morning injections preferred; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label concentration (1 mg/mL) and date; refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 4 weeks and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[11].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[12][13].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[12].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[14].
Materials & quantity planning
Source materials checklist · 2 mg
Plan based on a 4–8 week protocol with 2–3 injections per week.
-
Peptide Vials (Gonadorelin, 2 mg each):
- 4 weeks (100 mcg × 3/wk) ≈ 1 vial
- 6 weeks (100 mcg × 3/wk) ≈ 1 vial
- 8 weeks (150 mcg × 3/wk) ≈ 2 vials
-
Insulin Syringes (U‑100, 30‑ or 50‑unit preferred):
- Per week: 3 syringes
- 4 weeks: 12 syringes
- 6 weeks: 18 syringes
- 8 weeks: 24 syringes
-
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- 4–6 weeks (1 vial): 2 mL → 1 × 10 mL bottle
- 8 weeks (2 vials): 4 mL → 1 × 10 mL bottle
-
Alcohol Swabs: One for the vial stopper + one for the injection site each administration.
- Per week: 6 swabs (2/injection × 3 injections)
- 4 weeks: 24 swabs
- 6 weeks: 36 swabs
- 8 weeks: 48 swabs → recommend 1 × 100‑count box
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 2 mg per vial and 2 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
PubMed — GnRH agonists: gonadorelin, leuprolide, and nafarelin – overview of pharmacology and clinical applications (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 02
Source document
Mayo Clinic — Gonadorelin injection routes and indications for LH/FSH stimulation testing (opens in a new tab)www.mayoclinic.org
Back to overview ↑ - 03
Source document
Wikipedia — Gonadorelin pharmacology, pulsatile dosing, and clinical history (opens in a new tab)en.wikipedia.org
Back to overview ↑ - 04
Research publication
PMC — Gonadotropin‑releasing hormone analogs: pulsatile vs. continuous effects on FSH/LH (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Research publication
PubMed — Gonadotropin treatment for male hypogonadotropic hypogonadism – spermatogenesis and fertility (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
- 07
Research publication
PMC — Preserving fertility in the hypogonadal patient: hCG and GnRH therapy options (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 08
Research publication
PMC — Pulsatile gonadorelin pump induces earlier spermatogenesis in congenital HH men (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Research publication
PubMed — Application of GnRH in hypogonadotropic hypogonadism: diagnostic and therapeutic aspects (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Source document
Drugs.com — Gonadorelin injectable: uses, side effects, and warnings (opens in a new tab)www.drugs.com
Back to overview ↑ - 11
Research publication
PMC — Subcutaneous drug injection review: pharmacologic considerations (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 12
Public health resource
CDC — Vaccine administration: subcutaneous route (angle/site; no aspiration) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 13
Public health resource
CDC (Subcut Injection PDF) — Technique diagram and site guidance for subcutaneous injections (opens in a new tab)www.cdc.gov
Back to overview ↑ - 14
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.